Clinical Trials Logo

Postpartum Hemorrhage clinical trials

View clinical trials related to Postpartum Hemorrhage.

Filter by:

NCT ID: NCT04300452 Recruiting - Clinical trials for Postpartum Hemorrhage

Carbetocin Versus Ergometrin in the Prevention of Postpartum Hemorrhage

Start date: April 5, 2018
Phase: Phase 4
Study type: Interventional

In the present study will be compared Carbetocin with ergometrin in the prevention of postpartum haemorrhage (PPH) in parturients that are undergoing caesarean section and are not presenting risk factors for PPH. As indicators will be used intraoperative blood loss, as well as the value of hemoglobin and hematocrit 24 hours after the caesarian section.

NCT ID: NCT04244409 Recruiting - Cervical Cancer Clinical Trials

INvestigational Study Into Transplantation of the Uterus

INSITU
Start date: February 18, 2019
Phase:
Study type: Observational

Observational study on cohort of 10 women undergoing uterine transplantation using deceased donors

NCT ID: NCT04117243 Recruiting - Clinical trials for Post Partum Hemorrhage

Tranexamic Acid Versus Sublingual Misoprostol in Reducing Blood Loss During Elective CS in High Risk Cases

Start date: January 20, 2020
Phase: Phase 2
Study type: Interventional

The Efficacy and safety of Preoperative Intravenous Tranexamic acid versus Sublingual misoprostol in reducing blood loss during and after Elective Cesarean section among high risk pregnant cases.

NCT ID: NCT04044287 Recruiting - Clinical trials for Postpartum Hemorrhage

Misoprostol in the Prevention of Postpartum Haemorrhage

Start date: January 1, 2013
Phase: Phase 3
Study type: Interventional

Postpartum haemorrhage is a major contributor to maternal mortality in the developing world. The incidence is between 5 and 12% in Jamaica and varies depending on the route of delivery. Misoprostol is a uterotonic agent which has the potential to augment the effects of the standard parenteral oxytocic agents used as best practice in the active management of the third stage of labour, thereby reducing the risk of postpartum haemorrhage and its attendant complications. The Aim of the study is twofold: to show that this additive effect translates to a reduced postpartum haemorrhage rate and secondly to demonstrate reduced side effects of misoprostol resulting from the lower dose and the powdered sublingual administration.

NCT ID: NCT03824743 Recruiting - Clinical trials for Postpartum Hemorrhage

Balanced Crystalloids in Postpartum Hemorrhage

Start date: January 25, 2019
Phase:
Study type: Observational

Introduction: Obstetric hemorrhage is the most feared complication that can occur during childbirth and continues to be the leading cause of death in pregnant women worldwide, about 7 women die every hour in the world. This is defined as an accumulated loss of blood of more than 1000 mL with signs and symptoms of hypovolemia within 24 hours of the birth process. The main objective of resuscitation in these patients is precisely to reduce the deleterious effects that are generated from the depletion of volume and the altered capacity of oxygen transport. The current debate focuses on the safety and efficacy of each particular liquid during resuscitation and on improving long-term patient outcomes. At present, there is no conclusive evidence on the impact at the level of acid-base status, hydroelectrolytic balance and potential kidney injury with respect to the use of balanced solutions such as Plasma-Lyte or Ringer's Lactate. Objective: To determine the differences in the volume of liquids and blood products required with the use of balanced crystalloids (Ringer's Lactate or Plasma-Lyte) in patients with obstetric hemorrhage in the Hospital Universitario Fundación Santa Fe de Bogotá during 2018 - 2019. Design, Materials, and methods: Historical cohort analytical study. All patients over 18 years of age who present an obstetric hemorrhage defined as bleeding> 1000 mL or less associated with signs or symptoms of hemodynamic instability will be included. The most important exclusion criterion is the presence of active infection at the time of the event. Patients will be divided into two groups, those who underwent hydroelectrolytic resuscitation with Plasma-Lyte and Ringer Lactate. Results and conclusions With this study, we intend to describe the differences in the base acid status measured by arterial gases in patients with obstetric hemorrhage. The aim is to find a relationship between the different groups with clinical outcomes, such as days of ICU stay and hospitalization, blood transfusion requirement, electrolyte disorders, acute kidney injury and survival.

NCT ID: NCT03777696 Recruiting - Clinical trials for Cesarean Section Complications

Buccal Misoprostol and Intravenous Tranexamic Acid During Emergent Cesarean Delivery

Start date: January 1, 2019
Phase: N/A
Study type: Interventional

Purpose to evaluate the effects of buccal misoprostol with or without intravenous tranexamic acid (TA) in comparison with placebo on reducing post-partum hemorrhage in pregnant women undergoing emergent cesarean section

NCT ID: NCT03774524 Recruiting - Clinical trials for Cesarean Section Complications

Sublingual Misoprostol and Tranexamic Acid in Pregnant Women With Twin Pregnancy Undergoing Cesarean Section

Start date: January 1, 2019
Phase: N/A
Study type: Interventional

Purpose to evaluate the effects of sublingual misoprostol with or without intravenous tranexamic acid (TA) in comparison with placebo on reducing post-partum hemorrhage in pregnant women with twin pregnancy undergoing an elective cesarean section.

NCT ID: NCT03723031 Recruiting - Clinical trials for Hemorrhage, Postpartum

Intrauterine Misoprostol Versus Rectal Misoprostol in Reducing Blood Loss During Cesarean Section

Start date: November 15, 2018
Phase: Phase 2
Study type: Interventional

98 pregnant women attending for CS will be randomized into 2 groups. Rectal misopristol group who will receive 400 microgram misoprostol rectally preoperatively with urinary catheter insertion and intrauterine misopristol group will receive 400 microgram misoprostol intrauterine (200 microgram at each cornu) intraoperatively following the delivery of the placenta. The estimated blood loss for each patient will be measured and data of both groups will be compared.

NCT ID: NCT03395730 Recruiting - Clinical trials for Postpartum Haemorrhage With Retained Placenta

Intraumbilical Oxytocin Versus Placental Cord Drainage in the Management of 3rd Stage of Labor

Start date: September 30, 2017
Phase: Phase 2
Study type: Interventional

The aim of this study is to compare the effectiveness of intraumbilical oxytocin and placental cord drainage in the management of third stage of labor. Does the use of intraumbilical vein oxytocin injection or the use of Placental cord drainage can cause a reduction of blood loss, Hb level drop, the length of the third stage of labor and the incidence of manual removal of the retained placenta during the third stage of labor in pregnant women after delivery of the infant?

NCT ID: NCT03140033 Recruiting - Clinical trials for Hemorrhage Postpartum

Sublingual Misoprostol to Reduce Blood Loss During Elective Cesarean Delivery

Start date: July 2016
Phase: Phase 2
Study type: Interventional

Sublingual Misoprostol to Reduce Blood Loss During Elective Cesarean Delivery : A Randomized Controlled Trial